monoclonal antibodies

Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS

By MedXY 11/13/2025

This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention and therapy.

Gastroenterology news

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

By MedXY 10/28/2025

Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising therapeutic target for PSC.

Neurology news Public Health

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies

By MedXY 10/10/2025

Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventive approaches herald a new era in personalized dementia care.

Allergy & Immunology Clinical Updates Nephrology Specialties

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

By MedXY 08/24/2025

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-modifying therapeutic options.